Literature DB >> 11487563

Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only.

M Schwab, E Schaeffeler, C Marx, U Zanger, W Aulitzky, M Eichelbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11487563

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  13 in total

1.  Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.

Authors:  B A Kaskas; E Louis; U Hindorf; E Schaeffeler; J Deflandre; F Graepler; K Schmiegelow; M Gregor; U M Zanger; M Eichelbaum; M Schwab
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Medical approaches and future options in chronic active ulcerative colitis.

Authors:  J T Siveke; C Folwaczny
Journal:  Int J Colorectal Dis       Date:  2004-01-15       Impact factor: 2.571

3.  Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance.

Authors:  Sandeep Kirit Davavala; Devendra C Desai; Philip Abraham; Tester Ashavaid; Anand Joshi; Tarun Gupta
Journal:  Indian J Gastroenterol       Date:  2013-08-31

4.  Pretreatment determination of TPMT--state of the art in clinical practice.

Authors:  A Teml; E Schaeffeler; M Schwab
Journal:  Eur J Clin Pharmacol       Date:  2009-02-07       Impact factor: 2.953

5.  Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.

Authors:  Virginia L Priest; Evan J Begg; Sharon J Gardiner; Christopher M A Frampton; Richard B Gearry; Murray L Barclay; David W J Clark; Paul Hansen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  A Personalized Approach to Managing Inflammatory Bowel Disease.

Authors:  Michael J Kingsley; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-05

Review 7.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

8.  Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population.

Authors:  Edna Efrati; Lior Adler; Norberto Krivoy; Eli Sprecher
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

9.  Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.

Authors:  Hua-Wen Xin; Hui Xiong; Xiao-Chun Wu; Qing Li; Lei Xiong; Ai-Rong Yu
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

10.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.